THB001
Chronic Spontaneous Urticaria (CSU)
Key Facts
About Third Harmonic Bio
Third Harmonic Bio is advancing a novel therapeutic strategy focused on selectively inhibiting the KIT receptor, the master regulator of mast cells, to address severe allergic and inflammatory conditions. Its lead asset, THB001, is in Phase 1b development for chronic urticaria, with a preclinical program, THB222, targeting fibrosis via DDR1 inhibition. The company's strategy is to leverage its targeted platform to develop oral therapies with superior safety profiles for chronic use, aiming to capture significant value in large immunology markets. Having gone public in 2022, Third Harmonic operates as a focused, lean organization advancing its pipeline through key clinical milestones.
View full company profileAbout Third Harmonic Bio
Third Harmonic Bio is advancing a novel therapeutic strategy focused on selectively inhibiting the KIT receptor, the master regulator of mast cells, to address severe allergic and inflammatory conditions. Its lead asset, THB001, is in Phase 1b development for chronic urticaria, with a preclinical program, THB222, targeting fibrosis via DDR1 inhibition. The company's strategy is to leverage its targeted platform to develop oral therapies with superior safety profiles for chronic use, aiming to capture significant value in large immunology markets. Having gone public in 2022, Third Harmonic operates as a focused, lean organization advancing its pipeline through key clinical milestones.
View full company profileTherapeutic Areas
Other Chronic Spontaneous Urticaria (CSU) Drugs
| Drug | Company | Phase |
|---|---|---|
| Dupixent (dupilumab) | Regeneron | Phase 3 |
| Ozureprubart (RPT904) | RAPT Therapeutics | Phase 2 (Planned) |
| Remibrutinib (LOU064) | Novartis | Phase III |
| Barzolvolimab | Celldex Therapeutics | Phase 3 |